v3.26.1
Segment information
 3 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment information Segment information
The Company manages its operations as a single operating and reportable segment with a focus on developing and commercializing novel oncolytic immunotherapies in order to treat cancer. The Company defines its segments on the basis of the way in which internally reported financial information is regularly reviewed to analyze financial performance and make operating decisions. The Company’s Chief Operating Decision Maker ("CODM") is the Chief Executive Officer. The CODM reviews consolidated operating results, and uses the Company's loss from operations and consolidated net income (loss), in order to monitor actual results as compared to the budget, and to determine how best to allocate the Company's operating and capital resources, specifically as it relates to the Company's development programs.
The following table presents selected financial information with respect to the Company's single operating segment, including significant segment expenses by program, for the three months ended June 30, 2026 and 2025:
Three Months Ended
June 30,
20262025
Operating expenses:(Amounts in thousands)
Direct research and development expenses by program:
RP1 program costs by study:
IGNYTE$674 $3,452 
ARTACUS484 1,619 
CERPASS(270)1,208 
IGNYTE-37,950 4,861 
Other RP1 study costs1,399 4,422 
RP28,828 3,875 
RP3246 857 
Unallocated research and development expenses¹:29,966 37,549 
Selling, general and administrative18,970 32,579 
Total operating expenses68,247 90,422 
Loss from operations(68,247)(90,422)
Other (expense) income, net(1,519)$3,729 
Net loss(69,766)(86,693)
¹Includes personnel-related costs and other costs